key: cord-0697303-5lg285pf authors: Bassi, Abhinav; Arfin, Sumaiya; Joshi, Rohina; Bathla, Nikita; Hammond, Naomi E; Rajbhandari, Dorrilyn; Tirupakuzhi Vijayaraghavan, Bharath Kumar; Venkatesh, Balasubramanian; Jha, Vivekanand title: Challenges in operationalising clinical trials in India during the COVID-19 pandemic date: 2021-12-22 journal: Lancet Glob Health DOI: 10.1016/s2214-109x(21)00546-5 sha: f3af8f6a60e0ea534d480d378af3d170be822a85 doc_id: 697303 cord_uid: 5lg285pf nan The global outbreak of COVID-19 has had a substantial effect on the conduct of scientific research worldwide. More than 2000 trials registered on ClinicalTrials.gov were terminated because of the challenges of doing clinical research during the pandemic. 1 Our research group from the George Institute for Global Health initiated three trials (NCT04483960), 2,3 including the hydroxychloroquine prophylaxis evaluation (HOPE) trial in India, 2 but encountered several challenges that were unique to India in terms of the operationalisation and execution of these trials. This Comment provides insight into these challenges and presents possible solutions to facilitate the conduct of clinical trials during the current COVID-19 pandemic and during future pandemics. To facilitate research during the COVID-19 pandemic, the Indian Council of Medical Research approved a joint review of multicentre research by one main designated ethics committee to fast-track decision making. 4 However, in practice, individual hospital ethics committees rarely accepted previous review by the central ethics committee. Among the 42 sites participating in the COVID-19 trials coordinated by the George Institute for Global Health, only three accepted central ethics committee approval. The median (IQR) duration between submitting applications and ethics committee approval was 59ยท5 (28-73) days, with substantial delays introduced by infrequent meetings, adherence to the traditional format of initial scientific subcommittee review before full ethics committee review, and the mandate for legal approval for clinical trial agreements before considering the ethics application. Individual ethics committees raised Delays in approval from regulatory agencies Prioritise investigator-initiated trials of public health importance Expedite review of academic trials that address questions of public health importance Streamline regulatory approval processes with prescribed timelines for review of proposals Eliminate redundancy in approval processes 6 all sites insisted on receiving applications in their respective templates, adding to delays in approval. The extraordinary caseload in India and the reduced per capita workforce made the organisation of a combined-site start-up meeting for all sites unfeasible. Persistent electricity outages, poor inter net connectivity, and the large digital divide were some of the additional obstacles that the trial team had to negotiate at sites. Internet quality was inconsistent, meaning that accessing study websites for randomisation and entering data into electronic case record forms was difficult. Participants were reluctant to comply with the follow-up needed in clinical trials. For instance, electrocardiograms were recommended as a safety procedure in the HOPE trial. About 19% of the participants refused the procedure, because of pandemic-imposed travel barriers or general discomfort with having tests at health-care facilities during the peak pandemic period. The stigma associated with testing positive for or being at risk of acquiring COVID-19, 7 and the reported discrimination of affected individuals, was another barrier to recruitment to trials and to the assessment of primary outcomes. There was mixed messaging from various bodiesincluding leading research organisations-about the efficacy of COVID-19 treatments, despite an absence, at that stage, of scientific evidence supporting their use. For example, around the commencement of the HOPE trial, the Indian Council of Medical Research issued advisories recommending hydroxychloroquine for health-care workers as prophylaxis against SARS-CoV-2 infection on the basis of in-vitro and observational studies, 8 while simultaneously advocating proof-ofconcept studies to guide recommendations. Calls from the medical community-including an approach by the George Institute for Global Health, the sponsoring organisation of the HOPE trial-to the Indian Council of Medical Research for a randomised controlled trial of hydroxychloroquine went unheeded. Direct consequences were uncertainty in the minds of health-care workers, and a loss of clinical equipoise when enrolling participants into the control group of a trial, because clinicians felt legally vulnerable if hydroxychloroquine was not prescribed to health-care workers. Funding was also affected, with one funding agency citing the Indian Council of Medical Research advisory as a reason not to provide funding support for the HOPE trial. In addition, 8 months into the HOPE trial, the product advisory for Covaxin (Bharat Biotech, Hyderabad, India)-the COVID-19 vaccine developed in India-advised against the concomitant intake of chloroquine analogues, without providing supporting data. Therefore, health-care workers who were enrolled into the intervention group of the trial could not continue taking hydroxychloroquine if they had received Covaxin, which further stalled recruitment and trial conduct. Recommended strategies to facilitate the conduct of clinical trials in India are provided in the table. As part of future pandemic preparedness, India needs a coordinated strategy to facilitate pragmatic, investigator-led clinical trials-such as the UK RECOVERY trial-to rapidly answer questions of public health importance. The George Institute for Global Health The George Institute for Global Health Department of Critical Care Medicine Clinical trials stopped by COVID-19. The Grey Literature Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation (HOPE) trial: a structured summary of a study protocol for a randomized controlled trial Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan National guidelines for ethics committees reviewing biomedical and health research during COVID-19 pandemic Central Drugs Standard Control Organisation. New drugs and clinical trials rules Indian Council of Medical Research. Common forms for ethics committee review Challenges facing individuals and researchers: suicide in India in the COVID-19 pandemic National Taskforce for COVID-19. Revised advisory on the use of hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory dated We acknowledge the dedicated health-care workers who made a seminal contribution to patient care under very challenging circumstances. BV reports